Skip to main content
Zai Lab Limited logo

Zai Lab Limited — Investor Relations & Filings

Ticker · 9688 ISIN · KYG9887T1168 LEI · 549300P2UYQ9U5LY1T58 HKEX Manufacturing
Open in API
Filings indexed 388 across all filing types
Latest filing 2021-04-28 Capital/Financing Update
Country KY Cayman Islands
Listing HKEX 9688

About Zai Lab Limited

http://www.zailaboratory.com

Zai Lab Limited is an innovative, research-based, commercial-stage biopharmaceutical company dedicated to discovering, developing, and commercializing transformative therapies that address medical conditions with significant unmet needs. The company focuses its pipeline and development efforts across four core therapeutic areas: oncology, immunology, neuroscience, and infectious disease. Zai Lab employs a strategy of internal research and global partnerships to advance best-in-class and first-in-class medicines. A key commercial product is ZEJULA (niraparib), utilized as a maintenance treatment for ovarian cancer in markets including mainland China.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT
Capital/Financing Update Classification · 95% confidence The document is a voluntary announcement by Zai Lab Limited regarding the closing of an offering of ordinary shares and ADS offering. It includes details about the offering, pricing, and references to the registration statement filed with the SEC (Form S-3ASR). The document is an announcement of a financing event (share offering) rather than a full financial report or earnings release. It does not contain financial statements or detailed financial analysis but focuses on the capital raising activity. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is 6091 characters, which is consistent with an announcement rather than a full report. Hence, the classification is CAP with high confidence.
2021-04-28 English
VOLUNTARY ANNOUNCEMENT AND OVERSEAS REGULATORY ANNOUNCEMENT
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the closing of an offering of American Depositary Shares (ADS) and the full exercise of the greenshoe option. It references regulatory filings such as Form 8-K and Form S-3ASR with the SEC, and details the proceeds and terms of the offering. The document is a voluntary and overseas regulatory announcement about financing activity, specifically a capital raising event. It does not contain financial statements or detailed financial analysis, but rather an update on the capital raising transaction. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is 7109 characters, which is sufficient for a detailed announcement but not a full financial report. Hence, the classification is CAP with high confidence.
2021-04-25 English
OVERSEAS REGULATORY ANNOUNCEMENT
Capital/Financing Update Classification · 95% confidence The document is a regulatory announcement by Zai Lab Limited regarding the closing of an underwritten public offering of American Depositary Shares (ADSs) and the full exercise of the greenshoe option. It includes a Form 8-K filing with the U.S. Securities and Exchange Commission (SEC), which is a current report used to announce major events that shareholders should know about. The content focuses on financing activities, specifically the public offering and capital raising details, including the number of shares offered, pricing, and gross proceeds. There is no detailed financial statement or comprehensive financial analysis typical of annual or interim reports. The document is not a full annual report, earnings release, or management discussion but rather an update on capital raising activities. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (12,391 characters) and detailed content support this classification with high confidence.
2021-04-25 English
OVERSEAS REGULATORY ANNOUNCEMENT
Capital/Financing Update Classification · 100% confidence The document is an announcement related to a prospectus supplement filed with the U.S. Securities and Exchange Commission (SEC) for an underwritten offering of American Depositary Shares (ADSs) by Zai Lab Limited. It includes detailed information about the offering size, pricing, underwriting, and regulatory compliance. The document references the filing of a prospectus supplement and includes detailed offering terms, risk factors, use of proceeds, and other information typical of a securities offering document. This is a capital raising event involving issuance of shares and related securities. The document is not a financial report, earnings release, management discussion, or regulatory certification. It is a detailed update on a financing transaction and capital structure change. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is the actual offering document, not just an announcement of a report, so it is not RPA or RNS.
2021-04-22 English
OVERSEAS REGULATORY ANNOUNCEMENT
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the U.S. Securities and Exchange Commission, which is a current report pursuant to the Securities Exchange Act of 1934. It details the underwriting agreement for a significant offering of American Depositary Shares (ADSs) and ordinary shares, including terms of the offering, registration statements, and related agreements. The document is an announcement of a capital raising event and financing activity, specifically an underwritten offering of shares. It is not an annual or quarterly report, audit report, earnings release, or other types of filings. The content clearly fits the category of Capital/Financing Update, as it provides detailed information about the company's fundraising through share issuance and underwriting agreements. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence in this classification.
2021-04-22 English
OVERSEAS REGULATORY ANNOUNCEMENT
Capital/Financing Update Classification · 95% confidence The document is a regulatory announcement from Zai Lab Limited regarding the pricing of an underwritten public offering of American Depositary Shares and ordinary shares. It includes a Form 8-K filing with the U.S. Securities and Exchange Commission, which is a current report used to announce major events that shareholders should know about. The content focuses on the details of the capital raising transaction, including pricing, underwriters, and offering terms. There are no financial statements or comprehensive financial analysis typical of annual or interim reports. The document is not a full earnings release but rather an update on financing activity. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length is substantial and contains detailed information about the offering, supporting a high confidence level.
2021-04-21 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.